MyAV范

The imaging agent [¹⁸F]MK-6240 will be used by MyAV范 in clinical studies to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. These NFTs are a hallmark of several neurodegenerative diseases, including Alzheimer鈥檚 Disease. MyAV范 is the first site able to distribute GMP-produced [¹⁸F]MK-6240 in the United Kingdom.

Professor Erik Arstad, the Director of the MyAV范 Centre for Radiopharmaceutical Chemistry, said 鈥淭he team at the MyAV范 Centre for Radiopharmaceutical Chemistry is delighted to provide [¹⁸F]MK-6240 to our clinical collaborators at the MyAV范 Dementia Research Centre and the wider biomedical research community in the UK. As the best-in-class imaging biomarker for neurofibrillary tangles (NFTs) in the brain, [¹⁸F]MK-6240 will facilitate UK led research into the understanding and treatment of Alzheimer鈥檚 Disease.鈥�